And for many, it holds so much significance—from race, to culture, to identity. The spectrum of skin color and features is certainly something to celebrate, and these differences can also relate to disease prevalence, how diseases present, and how patients are impacted.
In Asian individuals, AD lesions may be more distinguishable with well-defined lesions, and with increased scaling and lichenification compared with White patients.1
Erythema, which often appears as pink or redness in lighter skin tones, may be harder to appreciate or assess in darker skinned AD patients, where redness may appear more violaceous in color or be missed completely.1
Asian individuals and Pacific Islanders are seven times more likely than White persons to be diagnosed with AD at an office visit.1
Although some studies have reported no statistically significant differences in the age of onset, duration, or type of alopecia areata (AA) by ethnicity, in one cross-sectional US registry, African Americans were 77% more likely to be diagnosed with AA than were White persons. More information is needed to understand whether AA prevalence varies by race and/or ethnicity.2-4
Vitiligo can place a significant psychosocial burden on people with darker skin types. In countries throughout the world, affected individuals may be treated as though they have an infectious disease or disfigurement and may face social stigmatization.5
That’s why we at Pfizer are doing our part to support all those in the healthcare and dermatology community who are paving the way toward a world in which patients of color feel truly seen and deeply understood. This includes:
Learn more about our commitment.